Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1

Active, not recruiting

Conditions: Gastrointestinal Stromal Tumor (GIST)

Interventions: Drug: MEK162
Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
Other: Blood draws
Procedure: biopsy

First Posted Date: 2013-11-25

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT01991379

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Pre-test Assessment
Behavioral: Pre test Counseling
Other: Blood draw
Behavioral: Post-test counseling, and post-test assessment
Behavioral: Follow-up assessments (6 and 12 months)

First Posted Date: 2013-11-25

Last Posted Date: 2017-12-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 197

Registration Number: NCT01992471

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Behavioral: The risk assessment questionnaire
Other: Blood specimens
Other: tumor tissue samples will be requested

First Posted Date: 2013-11-14

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 600

Registration Number: NCT01983410

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 10 locations

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Phase 2

Completed

Conditions: Advanced Epithelial Ovarian
Primary Peritoneal Carcinoma
Recurrent Epithelial Ovarian
Fallopian Tube

Interventions: Drug: Enzalutamide

First Posted Date: 2013-11-03

Last Posted Date: 2023-04-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT01974765

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 3 locations

Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis

Completed

Conditions: Brain Cancer

Interventions: Procedure: MRI

First Posted Date: 2013-11-03

Last Posted Date: 2022-12-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01974804

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Dexmedetomidine
Drug: Placebo

First Posted Date: 2013-10-31

Last Posted Date: 2024-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 333

Registration Number: NCT01973452

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States

and more 1 locations

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

Phase 2

Completed

Conditions: Esophageal Adenocarcinoma

Interventions: Device: MatriStem PSM

First Posted Date: 2013-10-28

Last Posted Date: 2023-11-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 78

Registration Number: NCT01970306

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Phase 1

Completed

Conditions: EGFR-Mutant Lung Cancer

Interventions: Drug: erlotinib

First Posted Date: 2013-10-22

Last Posted Date: 2018-11-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT01967095

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 2 locations

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Aerobic Training
Behavioral: Educational Information
Behavioral: Supervised Home Based Training

First Posted Date: 2013-09-17

Last Posted Date: 2024-07-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 144

Registration Number: NCT01943695

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Phase 1

Completed

Conditions: Intrahepatic Cholangiocarcinoma
Peripheral Cholangiocarcinoma
Cholangiocellular Carcinoma) (ICC)
Cholangiolar Carcinoma

Interventions: Procedure: Liver resection and placement of hepatic artery infusion pump
Drug: FLOXURIDINE
Drug: DEXAMETHASONE
Drug: GEMCITABINE

First Posted Date: 2013-09-10

Last Posted Date: 2020-09-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT01938729

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy